Photodynamic therapy of premalignant lesions and local recurrence of laryngeal and hypopharyngeal cancers.
The main advantage of photodynamic therapy (PDT) in laryngology seems to be its non-invasiveness and the possibility of using it despite previous application of conventional methods. In the study, we gave PDT to two separate groups of patients, i.e. five patients with advanced tumour (four of them with local recurrence (squamous cell carcinoma) after surgery and radiotherapy and one with a primary hypopharyngeal tumour) and five patients with leucoplakia. In the first group delta-aminolaevulinic acid (ALA) was administered orally (dose 3 g), while in the second, an ointment containing 10% ALA was applied locally. In both groups prior to irradiation, the tissue level of protoporphyrin IX was verified using an adapted Xillix Life instrument. All treated lesions were irradiated with an argon-pumped dye laser (dose range 100-250 J/cm2, wavelength 635 nm). In the first group, partial response was obtained. In these advanced cases, diminution of cancerous ulcerations was observed. In the leucoplakia group, complete response was achieved in four out of five treated patients. On the basis of our preliminary results, PDT may be useful in eradicating premalignant lesions of the oral cavity and in the palliation of advanced lesions of the oropharynx and larynx.
Sieron
A
A
Centre for Laser Diagnostics and Therapy, Department of Internal Diseases and Physical Medicine, Silesian Medical University, Katowice, Poland.
Namyslowski
G
G
Misiolek
M
M
Adamek
M
M
Kawczyk-Krupka
A
A
D000622:Aminolevulinic Acid / Q000008:administration & dosage / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000150:complications / Q000628:therapy*; D005260:Female; D006801:Humans; D007012:Hypopharyngeal Neoplasms / Q000150:complications / Q000628:therapy*; D007822:Laryngeal Neoplasms / Q000150:complications / Q000628:therapy*; D053685:Laser Therapy; D007971:Leukoplakia / Q000150:complications; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D009367:Neoplasm Staging; D016609:Neoplasms, Second Primary; D017319:Photosensitizing Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D010789:Phototherapy / Q000379:methods*; D011230:Precancerous Conditions / Q000628:therapy*
D017319:Photosensitizing Agents; D000622:Aminolevulinic Acid